4.2 Review

Dendrimer Architectonics to Treat Cancer and Neurodegenerative Diseases with Implications in Theranostics and Personalized Medicine

期刊

ACS APPLIED BIO MATERIALS
卷 4, 期 2, 页码 1115-1139

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acsabm.0c01319

关键词

dendrimer architecture; theranostics; personalized medicine; anticancer therapy; neurotheranostics

资金

  1. JNCASR, SwarnaJayanti Fellowship
  2. Department of Science and Technology (DST) [DST/SJF/CSA-02/2015-2016]
  3. DST-Nanomission, Govt. of India [SR/NM/TP-25/2016]
  4. Sheikh Saqr Laboratory (SSL), ICMS-JNCASR
  5. CSIR

向作者/读者索取更多资源

Theranostics, integrating diagnostic and therapeutic functions in a single platform, allows for noninvasive detection and treatment while monitoring disease progression and therapeutic efficacy in conditions like cancer and Alzheimer's disease. Theranostic tools can function independently or with the assistance of carriers like liposomes, micelles, polymers, or dendrimers, offering multifunctional properties for simultaneous imaging and drug delivery.
Integration of diagnostic and therapeutic functions in a single platform namely theranostics has become a cornerstone for personalized medicine. Theranostics platform facilitates noninvasive detection and treatment while allowing the monitoring of disease progression and therapeutic efficacy in case of chronic conditions of cancer and Alzheimer's disease (AD). Theranostic tools function by themselves or with the aid of carrier, viz. liposomes, micelles, polymers, or dendrimers. The dendrimer architectures (DA) are well-characterized molecular nanoobjects with a large number of terminal functional groups to enhance solubility and offer multivalency and multifunctional properties. Various noninvasive diagnostic tools like magnetic resonance imaging (MRI), computed tomography (CT), gamma scintigraphy, and optical techniques have been accomplished utilizing DAs for simultaneous imaging and drug delivery. Obstacles in the formulation design, drug loading, payload delivery, biocompatibility, overcoming cellular membrane and blood-brain barrier (BBB), and systemic circulation remain a bottleneck in translational efforts. This review focuses on the diagnostic, therapeutic and theranostic potential of DA-based nanocarriers in treating cancer and neurodegenerative disorders like AD and Parkinson's disease (PD), among others. In view of the inverse relationship between cancer and AD, designing suitable DA-based theranostic nanodrug with high selectivity has tremendous implications in personalized medicine to treat cancer and neurodegenerative disorders.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据